Stockscreener 앱 받기
28.88
0.37%
-0.131
Rigel Pharmaceuticals 주식(RIGL)의 최신 뉴스
[144] RIGEL PHARMACEUTICALS INC SEC Filing - Stock Titan
RIGL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $57 - GuruFocus
RIGL Stock Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Pharmaceuticals Presents GAVRETO Phase 3 Data at ASCO 2026 - Intellectia AI
META_TITLE_QUOTE - Yahoo Finance
Rigel cancer drugs post multi-year responses in lung and relapsed leukemia - Stock Titan
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock? - MSN
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story - Yahoo Finance
Rigel Pharmaceuticals, Inc. (RIGL) M&A CallSlideshow (NASDAQ:RIGL) 2026-05-20 - Seeking Alpha
Rigel Shareholders Approve Equity Plans and Board Slate - TipRanks
Rigel (RIGL) investors back equity plan, ESPP and auditor at 2026 meeting - Stock Titan
Rigel Pharmaceuticals Highlights Growth Amid Rising Costs - TipRanks
Pfizer Keeps Oncology Upside As Rigel Takes VEPPANU PROTAC Lead - simplywall.st
RIGEL (RIGL) director Kamil Ali-Jackson receives 5,750-share RSU board grant - Stock Titan
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug - MSN
Rigel Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals Q3 2025 Earnings Preview - MSN
Avoiding Lag: Real-Time Signals in (RIGL) Movement - Stock Traders Daily
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GuruFocus
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA‑Approved Breast Cancer Drug VEPPANU - simplywall.st
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
Armistice Capital (RIGL) reports 1.28M shares, 6.93% stake - Stock Titan
Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal - RTTNews
Rigel Pharmaceuticals inks worldwide agreement to develop and commercialize VEPPANU - Traders Union
Rigel Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference - Moomoo
These Analysts Increase Their Forecasts On Arvinas After Q1 Results - Sahm
Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, ArvinasHas The Bull Case Changed? - Yahoo Finance
RIGL Maintained by Citigroup -- Price Target Raised to $81.00 - GuruFocus
Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu | PharmExec - Pharmaceutical Executive
Rigel Pharmaceuticals Enters $85 Million Agreement for Exclusive Global Rights to Veppanu - Pharmaceutical Executive
New Haven biotech Arvinas signs potential $405M drug licensing deal - Hartford Business Journal
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $81 - Moomoo
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Raises Target Price to $81 - Moomoo
Rigel snaps up breast cancer drug Veppanu in up to $405m deal - The Pharma Letter
Rigel Pharmaceuticals Enters License Agreement for VEPPANU™ with Arvinas and Pfizer – 8-K Filing Details - Minichart
Pfizer PROTAC Licensing Deal With Rigel Adds Royalties To Valuation Story - simplywall.st
[8-K] RIGEL PHARMACEUTICALS INC Reports Material Event - Stock Titan
Rigel Pharmaceuticals inks deal with Arvinas and Pfizer for breast cancer drug VEPPANU, shares jump 10.7%. - Pluang
Pfizer (PFE) Enters Licensing Deal with Rigel Pharmaceuticals - GuruFocus
Rigel Pharmaceuticals stock rises on Veppanu licensing deal - Investing.com
Why Is Rigel PharmaceuticalsArvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE), Rigel Pharmaceuticals (NASDAQ:RI - Benzinga
Arvinas, Pfizer, and Rigel Partner on Veppanu (Vepdegestrant) Breast Cancer Drug - geneonline.com
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu - TipRanks
Biopharma bites: Rigel buys beleaguered PROTAC, Bayer's pipeline trim, and more from Novo Nordisk, Delos Capital - FirstWord Pharma
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside? - Stocktwits
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug - BioPharma Dive
Coming through on Veppanu with back-loaded Rigel deal - BioWorld News
Pfizer, Arvinas win $85M upfront in Rigel licensing pact for new breast cancer med Veppanu - Fierce Pharma
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer - TipRanks
Pfizer and Arvinas give disappointing breast cancer drug to Rigel - Endpoints News
Arvinas, Pfizer sell rights to VEPPANU to Rigel for $85 million - Investing.com UK
Arvinas Q1 Earnings Call Highlights - TradingView
Arvinas, Pfizer sell rights to VEPPANU to Rigel for $85 million By Investing.com - Investing.com South Africa
Statutory Earnings May Not Be The Best Way To Understand Rigel Pharmaceuticals' (NASDAQ:RIGL) True Position - simplywall.st
2.25%
0.46%
자본화:
|
볼륨(24시간):